U.S. markets open in 4 hours 7 minutes
  • S&P Futures

    4,276.25
    -0.50 (-0.01%)
     
  • Dow Futures

    33,954.00
    -9.00 (-0.03%)
     
  • Nasdaq Futures

    13,488.00
    -5.25 (-0.04%)
     
  • Russell 2000 Futures

    1,991.90
    +2.80 (+0.14%)
     
  • Crude Oil

    89.22
    +1.11 (+1.26%)
     
  • Gold

    1,779.70
    +3.00 (+0.17%)
     
  • Silver

    19.70
    -0.03 (-0.16%)
     
  • EUR/USD

    1.0169
    -0.0011 (-0.11%)
     
  • 10-Yr Bond

    2.8930
    0.0000 (0.00%)
     
  • Vix

    20.19
    +0.50 (+2.54%)
     
  • GBP/USD

    1.2048
    -0.0003 (-0.03%)
     
  • USD/JPY

    135.3100
    +0.2200 (+0.16%)
     
  • BTC-USD

    23,454.93
    -394.30 (-1.65%)
     
  • CMC Crypto 200

    557.55
    -15.27 (-2.66%)
     
  • FTSE 100

    7,509.54
    -6.21 (-0.08%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

Do Insiders Own Lots Of Shares In Mayne Pharma Group Limited (ASX:MYX)?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Mayne Pharma Group Limited (ASX:MYX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

With a market capitalization of AU$609m, Mayne Pharma Group is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about Mayne Pharma Group.

See our latest analysis for Mayne Pharma Group

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Mayne Pharma Group?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Mayne Pharma Group. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Mayne Pharma Group, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in Mayne Pharma Group. Our data shows that Mithra Pharmaceuticals SA is the largest shareholder with 9.6% of shares outstanding. In comparison, the second and third largest shareholders hold about 6.3% and 6.0% of the stock. Additionally, the company's CEO Scott Richards directly holds 1.8% of the total shares outstanding.

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Mayne Pharma Group

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

We can see that insiders own shares in Mayne Pharma Group Limited. It has a market capitalization of just AU$609m, and insiders have AU$56m worth of shares, in their own names. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

General Public Ownership

The general public, who are usually individual investors, hold a substantial 56% stake in Mayne Pharma Group, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

Private Company Ownership

We can see that Private Companies own 4.0%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Public Company Ownership

We can see that public companies hold 9.6% of the Mayne Pharma Group shares on issue. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Mayne Pharma Group better, we need to consider many other factors. Be aware that Mayne Pharma Group is showing 1 warning sign in our investment analysis , you should know about...

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here